Wells Fargo & Company Design Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
A detailed history of Wells Fargo & Company transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 14,415 shares of DSGN stock, worth $68,038. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,415
Previous 13,797
4.48%
Holding current value
$68,038
Previous $46,000
67.39%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding DSGN
# of Institutions
103Shares Held
30.8MCall Options Held
2.3KPut Options Held
16.5K-
Sr One Capital Management, LP6.53MShares$30.8 Million11.88% of portfolio
-
Logos Global Management LP San Francisco, CA4.22MShares$19.9 Million3.0% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$10.9 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.89MShares$8.93 Million0.55% of portfolio
-
Baker Bros. Advisors LP New York, NY1.74MShares$8.23 Million0.1% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $263M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...